Revolutionizing the Treatment of Endometrial Cancer by Leveraging the Potential of Immune Checkpoint Inhibitors

This activity was originally broadcast as part of the 2023 Directions in Oncology Pharmacy conference.

• Note: The patient case discussion portion of the program also includes discussion on ovarian cancer.

Program Description
Until recently, platinum doublet chemotherapy has been the standard of care in patients with advanced or recurrent endometrial cancer as there were no optimal treatment options after progression on first-line therapy. Immune checkpoint inhibitors (ICIs) have entered the treatment landscape of endometrial cancer with proven anti-tumor activity as both monotherapy and in combination. Oncology pharmacists must be familiar with treatment sequencing and individualized management of ICI-based therapies for patients with advanced or recurrent disease based on patient factors and disease characteristics. The novel mechanisms of action of ICIs also present potential for delayed-onset immune-related adverse effects (irAEs), such as endocrinopathies. The program will review evidence-based strategies for the integration of ICIs into current regimens and treatment paradigms for endometrial cancer. A patient case discussion will follow the presentation and address guideline recommendations for the management of irAEs and strategies for oncology pharmacists to provide supportive care to patients with endometrial cancer.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: November 22, 2023
Expiration date: November 22, 2024
Learner level: Foundational, intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate the relationship between mismatch repair status, microsatellite instability, and treatment response in advanced or recurrent endometrial cancer
• Analyze recent and emerging clinical evidence supporting the use of immune checkpoint inhibitors in the treatment of advanced or recurrent endometrial cancer
• Employ evidence-based strategies for the prevention and management of immune-mediated endocrinopathies to individualize treatment protocols for patients with advanced or recurrent endometrial cancer
• Apply knowledge of genomic mutations, clinical evidence, treatment guidelines, and immune-mediated toxicity management to real-world patient case scenarios

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-439-H01-P. The activity is available for CE credit through November 22, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Jennifer MacDonald, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Speakers Bureau: GSK
Advisory Board: Mersana

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Medical reviewer Eric Fela, PharmD, BCOP, has the following relevant financial relationships with commercials interest to disclose:
Speakers Bureau: Merck
Other (educational grant): GSK

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms